Cardiol Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
Thank you for joining us. My name is Edward Nash. I am a Senior Analyst on the Biotech team here at Canaccord Genuity.
It is my pleasure to have with us today the management team of Cardiol Therapeutics. Cardiol is a name that we currently cover with a buy rating. And it's one of the, I think, more interesting names for sure, and have a limited number of names, which makes it even more interesting, I believe, in the cardiology space.
With us, we have David Elsley, who is the President and Chief Executive Officer; and Dr. Andrew Hammer, who is the Chief Medical Officer. And I'll have David give the presentation, and then we'll have perhaps a little bit of time after for any Q&A. With that, I'll turn it over to you, David.
Okay. Thanks, Edward, and good morning, everyone. It's a great pleasure to have the opportunity to present Cardiol Therapeutics. I've had the great pleasure of working in the area of heart medicine
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
